CHICAGO, May 1, 2017 /PRNewswire/ -- Coapt, LLC, the only provider of commercially available, intuitive control systems for advanced prosthetic arms, today announced it has obtained the Food and Drug Administration's Class II medical device clearance for its COMPLETE CONTROL System. It is the first and only myoelectric pattern recognition system to be cleared for marketing in the United States by the FDA. This clearance indicates the device's high level of safety and effectiveness.
This FDA clearance is another "first" from the leading biomedical engineering firm. Coapt currently brings cutting-edge technology to some of the more than 100,000 upper-limb amputees and those with congenital limb differences in the United States, allowing them to participate in work and daily routines with ease. Its plug-and-play hardware seamlessly integrates with every major powered prosthetic arm component, making it simple for users — from utility workers to farmers to lawyers — to regain their independence with minimal training time.
"Earning an FDA Class II clearance for this technology is an incredible milestone for Coapt and for the profession," said Matthew Garibaldi, MS, CPO, Director, Orthotic and Prosthetic Centers, and Associate Clinical Professor, Department of Orthopaedic Surgery at the University of California, San Francisco. "This achievement sets a new precedent in prosthetic device innovation."
"We're constantly pushing forward the limits of technology to allow our users better, safer, more reliable control of their upper-limb prostheses," said Blair Lock, co-founder and CEO of Coapt. "The FDA Class II medical device clearance is another indication that our product is a high-quality solution for advanced prosthetic arms. As an industry leader in the field of intuitive control, Coapt never stops innovating."
Coapt's COMPLETE CONTROL System uses groundbreaking pattern recognition technology to decode the electrical signals that a user's remaining muscles make as the brain sends information to the absent limb, enabling the user to move the prosthesis intuitively. This gives the user unprecedented limb control, far beyond what is possible with existing prostheses alone, which often feel unnatural and uncomfortable to control.
"Until the advent of pattern recognition technology, the evolution of upper extremity prosthetic hardware had far exceeded the capability of traditional control mechanisms. Thus, highly technical and capable prosthetic applications had in large part been wholly underutilized," said Garibaldi. "Pattern recognition unlocks the potential of prosthetic users by allowing for discrimination of multiple degrees of freedom and simultaneous control – meaning, they can move their prostheses in more ways, in a manner more like a natural upper limb."
Founded in 2012, Coapt is the first and only company to provide revolutionary and intuitive control technology for advanced prosthetic arms. Started by four leading researchers in the bionics field, Coapt is based on years of research and clinical care at the nation's leading hospital for comprehensive physical medicine and rehabilitation, the Shirley Ryan AbilityLab (formerly the Rehabilitation Institute of Chicago). Coapt is an award-winning company that strives to improve the quality of life for prosthesis users by applying clinically dedicated engineering to its portfolio of transformative technologies. For more information, visit www.coaptengineering.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/coapt-now-first-and-only-advanced-myoelectric-control-system-with-fda-class-ii-clearance-300448734.html